Journal
EUROPEAN RADIOLOGY
Volume 32, Issue 9, Pages 5921-5929Publisher
SPRINGER
DOI: 10.1007/s00330-022-08725-3
Keywords
Machine learning; PET-CT; Lymphadenopathy; COVID-19 vaccine; Breast cancer
Ask authors/readers for more resources
The study aimed to differentiate between FDG-avid breast cancer metastatic lymphadenopathy and FDG-avid COVID-19 mRNA vaccine-related axillary lymphadenopathy using machine learning and radiomics. The results demonstrated that radiomics features can effectively differentiate between the two conditions, which may have clinical significance in distinguishing between benign and malignant lymph nodes.
Objectives To evaluate if radiomics with machine learning can differentiate between F-18-fluorodeoxyglucose (FDG)-avid breast cancer metastatic lymphadenopathy and FDG-avid COVID-19 mRNA vaccine-related axillary lymphadenopathy. Materials and methods We retrospectively analyzed FDG-positive, pathology-proven, metastatic axillary lymph nodes in 53 breast cancer patients who had PET/CT for follow-up or staging, and FDG-positive axillary lymph nodes in 46 patients who were vaccinated with the COVID-19 mRNA vaccine. Radiomics features (110 features classified into 7 groups) were extracted from all segmented lymph nodes. Analysis was performed on PET, CT, and combined PET/CT inputs. Lymph nodes were randomly assigned to a training (n = 132) and validation cohort (n = 33) by 5-fold cross-validation. K-nearest neighbors (KNN) and random forest (RF) machine learning models were used. Performance was evaluated using an area under the receiver-operator characteristic curve (AUC-ROC) score. Results Axillary lymph nodes from breast cancer patients (n = 85) and COVID-19-vaccinated individuals (n = 80) were analyzed. Analysis of first-order features showed statistically significant differences (p < 0.05) in all combined PET/CT features, most PET features, and half of the CT features. The KNN model showed the best performance score for combined PET/CT and PET input with 0.98 (+/- 0.03) and 0.88 (+/- 0.07) validation AUC, and 96% (+/- 4%) and 85% (+/- 9%) validation accuracy, respectively. The RF model showed the best result for CT input with 0.96 (+/- 0.04) validation AUC and 90% (+/- 6%) validation accuracy. Conclusion Radiomics features can differentiate between FDG-avid breast cancer metastatic and FDG-avid COVID-19 vaccine-related axillary lymphadenopathy. Such a model may have a role in differentiating benign nodes from malignant ones.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available